Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.
Pressure Biosciences CEO Rick Schumacher discusses the company’s proprietary technology and the high-profile clients that are using it.
OneMedPlace recently sat down with Jeffrey Davis, CEO of Access Pharmaceuticals, to discuss the clinical success of MuGard and the latest news surrounding the product’s launch.
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
BioNeutral, a life science company that specializes in biohazard neutralization technologies, has started shipping its Ogiene-M formulation to fulfill an agreement between BioNeutral and Mr. Mold.
HealthTronics announced that it has entered into a definitive merger agreement with Endocare.
Sensimed, a Swiss company focused on the development of integrated micro-systems for medical devices, has received the Red Herring 100 Europe 2009 Award.
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
Copyright © 2024 | WordPress Theme by MH Themes